GEn1E Lifesciences
vendor · www.gen1e.com
GEn1E Lifesciences is a Clinical-stage, multi-target company with a unique AI platform. We develop novel, next-generation, immunomodulatory therapies for rare & inflammatory diseases with no effective treatments. Our team is supercharging the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform capabilities—creating novel therapeutics at an unprecedented pace. Our AI platform has enabled us to develop a purpose-built therapy for ARDS to reduce its $20 billion cost on society (just in the USA). GEn1E has built a rich pipeline of 21+ novel and selective immunomodulators and has plans to accelerate 2 additional devastating diseases (beyond their lead indication) to IND in the next 12 months. Our AI platform enables tremendous pace and capital efficiency as demonstrated by our progress in ~2 years with seed capital—a stark contrast
About
GEn1E Lifesciences is a maker — it sells what it builds, with nothing priced here yet.
Nothing it sells has been priced into the catalogue yet — the company is here as a name the market uses, and the page will fill as its prices are read.
Every current figure
- Kind
- vendor
- Home
- https://www.gen1e.com